Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation

@article{Coleman2012EffectOP,
  title={Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation},
  author={Craig I. Coleman and Diana M Sobieraj and Sara Winkler and Peter Cutting and Malek Mediouni and Sabina Alikhanov and Jeffrey Kluger},
  journal={International Journal of Clinical Practice},
  year={2012},
  volume={66}
}
Various antiplatelet and anticoagulation options are available for stroke prevention in patients with atrial fibrillation (AF). Currently, it is unclear whether these agents differ in their propensity to cause major gastrointestinal bleeding (MGIB). To our knowledge, no systematic evaluation of MGIB rates from randomised controlled trials (RCTs) of pharmacological stroke prevention in patients with AF has been conducted. Two independent investigators conducted systematic literature searches in… Expand
Risk of Gastrointestinal Bleeding in Patients Taking Non–Vitamin K Antagonist Oral Anticoagulants: A Systematic Review and Meta‐analysis
TLDR
Risk of major GI bleeding to be similar between NOACs and conventional anticoagulation is found, while Dabigatran and rivaroxaban may be associated with increased odds of majorGI bleeding. Expand
Oral antithrombotic therapy and gastrointestinal bleeding: the good, the bad and the ugly
TLDR
A systematic review of major gastrointestinal bleeding related to antithrombotic therapies in AF found that aspirin increased by more than threefold the odds of MGIB compared with placebo or control, although this did not reach the level of statistical significance, as the data were derived from three trials with small event rates in each arm. Expand
Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults – a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing
TLDR
New oral anticoagulant use among adults aged ≥65 years with atrial fibrillation appears to reduce haemorrhagic strokes and intracranial bleedings more effectively than VKAs and should be considered especially in patients with low TTR (time in therapeutic range)/labile INR (International Normalized Ratio). Expand
Costs of major intracranial, gastrointestinal and other bleeding events in patients with atrial fibrillation – a nationwide cohort study
TLDR
The societal costs attributable to major bleeding events in patients with AF are significant and intracranial haemorrhages are most costly to society with average costs of similar magnitude as the costs of ischemic stroke. Expand
Oral anticoagulant therapy in atrial fibrillation patients at high stroke and bleeding risk.
TLDR
Evidence shows that the absolute benefits of OAC are the greatest in patients at the highest risk, and NOACs may offer even a greater net clinical benefit compared to warfarin particularly in these high risk patients. Expand
Screening for Atrial Fibrillation With Electrocardiography: Evidence Report and Systematic Review for the US Preventive Services Task Force
TLDR
Although screening with ECG can detect previously unknown cases of atrial fibrillation, it has not been shown to detect more cases than screening focused on pulse palpation, and harms. Expand
The Population-Based Long-Term Impact of Anticoagulant and Antiplatelet Therapies in Low-Risk Patients With Atrial Fibrillation.
TLDR
In low-risk AF patients with a CHADS2 score of 0 to 1 or CHA2DS2-VASc score of0 to 2, the use of aspirin, clopidogrel, and warfarin was not associated with lower stroke rates at 5 years compared with no therapy, however, theUse of antithrombotic agents was associated with a significant risk of bleed. Expand
Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation and recent major bleeding event
A 76-year old female patient was referred to our hospital for consultation regarding further treatment for permanent atrial fibrillation (AF) of unknown duration, accidentally detected 2.5 years agoExpand
Novel oral anticoagulants in gastroenterology practice.
TLDR
For the first time in over 50 years, novel oral anticoagulants (NOACs) are available and contribute to its underuse in eligible patients with AF, and even when warfarin is given, the INR is frequently outside the therapeutic range. Expand
Benefit–Risk Assessment of Dabigatran in the Treatment of Stroke Prevention in Non-Valvular Atrial Fibrillation
TLDR
Dabigatran confers an advantage over warfarin regarding stoke prevention without the burden of the surveillance of vitamin K antagonists, especially in patients with high stroke risk, however, in elderly patients with impaired renal function or considerable bleeding risks, label advice regarding dosing needs strict observation. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 48 REFERENCES
Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial.
TLDR
For prevention of stroke in patients with NVAF, aspirin at 150 to 200 mg per day does not seem to be either effective or safe, and further prospective studies are needed to determine the best preventive therapy for cerebrovascular events in Japanese patients withNVAF. Expand
Bleeding risk in patients with atrial fibrillation: the AMADEUS study.
TLDR
Combination antithrombotic therapy increases the risk of clinically relevant bleeding and major bleeding in patients with atrial fibrillation and does not appear to reduce therisk of stroke. Expand
Effect of clopidogrel added to aspirin in patients with atrial fibrillation.
TLDR
In patients with atrial fibrillation for whom vitamin K-antagonist therapy was unsuitable, the addition of clopidogrel to aspirin reduced the risk of major vascular events, especially stroke, and increased the riskof major hemorrhage. Expand
Anticoagulant (Fluindione)-Aspirin Combination in Patients with High-Risk Atrial Fibrillation
TLDR
The combination of aspirin with anticoagulant is associated with increased bleeding in elderly atrial fibrillation patients and could not be accurately assessed in this study due to the limited number of ischemic events. Expand
Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
TLDR
The results establish the efficacy of fixed-dose oral ximelagatran without coagulation monitoring compared with well-controlled warfarin for prevention of thromboembolism in patients with atrial fibrillation requiring chronic anticoagulant therapy, but the potential for hepatotoxicity requires further investigation. Expand
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
TLDR
In high-risk patients with atrial fibrillation, fixed-dose oral ximelagatran was at least as effective as well-controlled warfarin for prevention of stroke and systemic embolism. Expand
Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators.
TLDR
Advancing age and more intense anticoagulation increase the risk of major hemorrhage in patients given warfarin for stroke prevention. Expand
Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia.
TLDR
To achieve optimal levels of anticoagulation with the lowest risk in patients with atrial fibrillation and a recent episode of cerebral ischemia, the target value for the INR should be set at 3.0, and values below 2.0 and above 5.0 should be avoided. Expand
Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. SIFA (Studio Italiano Fibrillazione Atriale) Investigators.
TLDR
Indobufen, a reversible inhibitor of platelet cyclooxygenase, with warfarin may help the medical community in devising appropriate antithrombotic strategies for NRAF patients for whom oral anticoagulants are contraindicated or do not represent a feasible approach to treatment. Expand
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial.
TLDR
Oral anticoagulation therapy is superior to clopidogrel plus aspirin for prevention of vascular events in patients with atrial fibrillation at high risk of stroke, especially in those already taking oral anticoAGulation therapy. Expand
...
1
2
3
4
5
...